Trial Profile
The Effect of CYP3A Induction by Rifampicin on the Pharmacokinetics of Baricitinib in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary) ; Rifampicin
- Indications Diabetic neuropathies; Psoriasis; Rheumatoid arthritis
- Focus Pharmacokinetics
- 30 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Oct 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.